单位:[1]Peking University Hepatology Institute, Peking University People’s Hospital[2]Ruijin Hospital[3]Xiangya Hospital Central South University[4]Shanghai Public Health Center[5]Guangzhou Eighth Municipal People’s Hospital[6]West China Hospital of Sichuan University四川大学华西医院[7]Beijing Ditan Hospital Capital Medical University[8]1st Hospital of Jilin University[9]Jinan Infectious Disease Hospital[10]Shengjing Hospital of China Medical University中国医科大学附属盛京医院[11]The Third Hospital of Hebei Medical University[12]Tongji Hospital[13])Shanghai Renji Hospital[14]Gilead Sciences, Inc[15]Gilead Sciences Inc., Foster City, California, USA[16]The Second Hospital of Nanjing[17]Peking University First Hospital[18]The Second Affiliated Hospital of Chongqing Medical University[19]The First Affiliated Hospital of Nanchang University[20]The Third Affiliated Hospital of Sun Yat-Sen University中山大学附属第三医院[21]Hainan General Hospital[22]Henan Provincial People’s Hospital[23]The Second Xiangya Hospital of Central South University[24]Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University江苏省人民医院[25]Shanghai Public Health Clinical Center[26]Beijing Youan Hospital, Capital Medical University[27]Nanfang Hospital[28]Beijing Friendship Hospital首都医科大学附属北京友谊医院
第一作者单位:[1]Peking University Hepatology Institute, Peking University People’s Hospital
推荐引用方式(GB/T 7714):
Wei Lai,Xie Qing,Huang Yan,et al.Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial[J].HEPATOLOGY.2018,68:379A-379A.
APA:
Wei, Lai,Xie, Qing,Huang, Yan,Wu, Shanming,Xu, Min...&Jia, Jidong.(2018).Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial.HEPATOLOGY,68,
MLA:
Wei, Lai,et al."Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial".HEPATOLOGY 68.(2018):379A-379A